SVB Leerink Maintains Market Perform on Rubius Therapeutics, Lowers Price Target to $3
SVB Leerink analyst Jonathan Chang maintains Rubius Therapeutics (NASDAQ:RUBY) with a Market Perform and lowers the price target from $5 to $3.
Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
Rubius Therapeutics Inc (NASDAQ: RUBY) has
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million.
87 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit.
SVB Leerink Maintains Market Perform on Rubius Therapeutics, Lowers Price Target to $5
SVB Leerink analyst Jonathan Chang maintains Rubius Therapeutics (NASDAQ:RUBY) with a Market Perform and lowers the price target from $14 to $5.
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell
• ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million.
Rubius Therapeutics Earnings Preview
Rubius Therapeutics (NASDAQ:RUBY) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement.
Analysts estimate that Rubius Therapeutics will report an earnings per share (EPS) of $-0.59.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
